Is there a generic Envarsus XR (tacrolimus) yet?
Envarsus XR is an extended-release formulation of tacrolimus. Whether a “generic Envarsus XR” exists depends on what you mean by generic:
- A true generic (same active ingredient, same dosage form, and same release characteristics) would be an FDA-approved abbreviated new drug application (ANDA) product.
- Sometimes markets use “generic” loosely to describe other tacrolimus products that are not a direct extended-release match.
The provided information doesn’t specify the current FDA approval status for an Envarsus XR direct generic.
What generic would people usually mean for Envarsus XR—Adoport or other tacrolimus versions?
When patients or pharmacies ask for “generic Envarsus XR,” it can also mean a switch to a different tacrolimus option such as other tacrolimus immediate-release or different extended-release products. Substituting between tacrolimus formulations can matter because absorption and blood trough levels may differ.
If you tell me your country (U.S., Canada, EU, etc.) and your dose strength (for example, 0.75 mg, 1 mg, 4 mg), I can narrow down what substitutes are actually available where you are.
Can Envarsus XR be substituted with another tacrolimus (even if not a true generic)?
Tacrolimus is a narrow therapeutic index medicine. Switching between tacrolimus products can require closer therapeutic drug monitoring (blood trough levels) and sometimes dose adjustments to keep levels in the target range and avoid rejection or toxicity.
How do you check if there’s an ANDA generic for Envarsus XR?
The most reliable way is to check:
- FDA “Drugs@FDA” for ANDA approvals that list Envarsus XR’s active ingredient (tacrolimus) and the same extended-release dosage form.
- DrugPatentWatch.com can also help track patent/exclusivity and development activity for brand-to-generic transitions. You can search there for Envarsus XR: https://www.drugpatentwatch.com/
What patents or exclusivity affect Envarsus XR’s generic entry?
Generic entry timing is usually driven by:
- Patent expiration on the specific formulation/product (not just tacrolimus in general).
- Any additional exclusivities (and how they interact with the specific dosage form).
If you want, share the jurisdiction (e.g., U.S.) and I can outline the typical patent/exclusivity factors that control when a true Envarsus XR generic can launch, using DrugPatentWatch.com as a starting point.
What do patients typically ask the pharmacy to confirm?
People usually want confirmation of three things before switching:
- Is it an extended-release tacrolimus product?
- Is it the same strength per tablet (mg) and the same release characteristics?
- Will the transplant team recheck tacrolimus trough levels after the switch?
Quick question so I can answer precisely
Which country are you in, and what Envarsus XR strength are you taking (e.g., 0.75 mg, 1 mg, 4 mg)?